ATE143698T1 - Modifizierte pf4-zusammensetzung und methoden zu deren verwendung - Google Patents

Modifizierte pf4-zusammensetzung und methoden zu deren verwendung

Info

Publication number
ATE143698T1
ATE143698T1 AT90307203T AT90307203T ATE143698T1 AT E143698 T1 ATE143698 T1 AT E143698T1 AT 90307203 T AT90307203 T AT 90307203T AT 90307203 T AT90307203 T AT 90307203T AT E143698 T1 ATE143698 T1 AT E143698T1
Authority
AT
Austria
Prior art keywords
modified
composition
methods
angiogenesis
mutant
Prior art date
Application number
AT90307203T
Other languages
English (en)
Inventor
Theodore E Maione
Original Assignee
Repligen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repligen Corp filed Critical Repligen Corp
Application granted granted Critical
Publication of ATE143698T1 publication Critical patent/ATE143698T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Dental Preparations (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT90307203T 1989-07-06 1990-07-02 Modifizierte pf4-zusammensetzung und methoden zu deren verwendung ATE143698T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/376,333 US5112946A (en) 1989-07-06 1989-07-06 Modified pf4 compositions and methods of use

Publications (1)

Publication Number Publication Date
ATE143698T1 true ATE143698T1 (de) 1996-10-15

Family

ID=23484594

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90307203T ATE143698T1 (de) 1989-07-06 1990-07-02 Modifizierte pf4-zusammensetzung und methoden zu deren verwendung

Country Status (9)

Country Link
US (1) US5112946A (de)
EP (2) EP0407122B1 (de)
JP (1) JPH0363297A (de)
AT (1) ATE143698T1 (de)
CA (1) CA2019086A1 (de)
DE (1) DE69028739T2 (de)
DK (1) DK0407122T3 (de)
ES (1) ES2092493T3 (de)
GR (1) GR3021658T3 (de)

Families Citing this family (325)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5800820A (en) * 1989-01-10 1998-09-01 Repligen Corporation Methods and compositions for treatment of angiogenic diseases
CA2113206A1 (en) * 1991-07-15 1993-02-04 Theodore E. Maione Modified pf4 compositions and methods of use
JPH06506702A (ja) * 1992-01-16 1994-07-28 レプリゲン　コーポレーション 脈管形成性の病気の処置用の新規な方法と組成物
US5304542A (en) * 1992-08-28 1994-04-19 University Of Louisville Research Foundation, Inc. Use of platelet factor 4 to inhibit osteoblast proliferation
ZA936925B (en) * 1992-09-25 1995-03-20 Lilly Co Eli Modified platelet factor-4.
WO1994010331A1 (en) * 1992-10-29 1994-05-11 The Australian National University Angiogenesis inhibitory antibodies
EP0900804A2 (de) * 1993-03-01 1999-03-10 Glycan Pharmaceuticals, Inc. Analoge für spezifische Oligosaccharide-Protein-Wechselwirkungen und ihre Verwendungen
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
MX9401807A (es) * 1993-03-12 1995-01-31 Xoma Corp Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas.
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5585095A (en) * 1993-09-14 1996-12-17 Regents Of The University Of Minnesota Method to enhance thrombomodulin APC generation using cationic proteins
AU1171795A (en) * 1993-11-05 1995-05-23 Repligen Corporation Novel modified pf4 compositions and methods of use
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
ATE208633T1 (de) * 1994-09-16 2001-11-15 Merck Patent Gmbh Immunokonjugate
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
EP0888086B1 (de) 1996-02-15 2005-07-27 Biosense Webster, Inc. Sonde zur exkavation
CN1226172A (zh) 1996-05-31 1999-08-18 斯克里普斯研究学院 用于抑制血管发生的方法和组合物
US6443974B1 (en) 1996-07-28 2002-09-03 Biosense, Inc. Electromagnetic cardiac biostimulation
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
CA2278937A1 (en) * 1996-12-11 1998-06-18 Pharmacyclics, Inc. Use of a texaphyrin in the preparation of a medicament for use in ocular diagnosis and therapy
DE69824853T2 (de) 1997-02-11 2006-01-12 Qlt Inc., Vancouver Zusammensetzung und Gegenstände zur Verminderung der Auswirkung von Entzündungen
US6274614B1 (en) 1997-02-11 2001-08-14 Qlt Inc. Methods, compositions and articles for reducing or preventing the effects of inflammation
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
EP1563866B1 (de) 1998-02-05 2007-10-03 Biosense Webster, Inc. Gerät zum Freisetzen eines Medikaments im Herzen
ATE490980T1 (de) 1998-03-19 2010-12-15 Human Genome Sciences Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
US20040022788A1 (en) * 1998-05-19 2004-02-05 Moser Tammy L. Compositions and methods for promoting or inhibiting angiogenesis
AU6409499A (en) * 1998-10-01 2000-04-17 Children's Medical Center Corporation Method of treatment of cardiovascular injuries
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US6454789B1 (en) 1999-01-15 2002-09-24 Light Science Corporation Patient portable device for photodynamic therapy
WO2000041726A2 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
EP1149168A2 (de) * 1999-02-01 2001-10-31 Beth Israel Deaconess Medical Center Comp/tsp-1, comp/tsp-2 und andere chimerische proteinen
EP2357192A1 (de) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
EP1183051A2 (de) * 1999-03-15 2002-03-06 Chiron Corporation Verwendung von rekombinanten expressionsvektoren zur behandlung oder vorbeugung von augenkrankheiten
US7261881B1 (en) 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
CN1434727A (zh) 1999-12-22 2003-08-06 斯克里普斯研究学院 血管发生和血管通透性调节剂及抑制剂
EP1267935A2 (de) 2000-01-12 2003-01-02 Light Sciences Corporation Behandlung von augenerkrankungen
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
DE60143798D1 (de) 2000-06-16 2011-02-17 Cambridge Antibody Tech Immunspezifisch bindende antikörper gegen blys
EP2412384A1 (de) 2000-11-28 2012-02-01 MedImmune, LLC Verfahren zur Verabreichung/Dosierung von Anti-RSV-Antikörpern zur Prophylaxe und Behandlung
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
EP1683865A3 (de) 2001-02-02 2006-10-25 Eli Lilly & Company Säugerproteine und insbesondere CD200
US6815426B2 (en) * 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
AU2002322478A1 (en) * 2001-03-02 2002-12-16 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
WO2002083704A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
JP4309758B2 (ja) 2001-05-25 2009-08-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Ｔｒａｉｌレセプターに免疫特異的に結合する抗体
US20070015144A9 (en) * 2001-05-25 2007-01-18 Genset, S.A. Human cDNAs and proteins and uses thereof
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
EP1534739A4 (de) * 2002-01-18 2006-05-31 Bristol Myers Squibb Co Identifizierung von polynukleotiden und polypeptid zur vorhersage der aktivität von verbindungen, die mit protein-tyrosinkinasen und/oder protein-tyrosinkinasewegen wechselwirken
AU2003218456A1 (en) * 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
EP2270049A3 (de) 2002-04-12 2011-03-09 Medimmune, Inc. Rekombinante Anti-Interleukin-9-Antikörper
ES2377720T3 (es) 2002-05-10 2012-03-30 Purdue Research Foundation Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos.
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
US20040265315A1 (en) * 2002-09-05 2004-12-30 Christine Dingivan Methods of preventing or treating T cell malignancies by administering CD2 antagonists
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
MXPA05003884A (es) 2002-10-16 2005-10-05 Euro Celtique Sa Anticuerpos que enlazan polipeptidos ca 125/0772p a celulas asociadas y metodos de uso de los mismos.
JP2006518997A (ja) * 2003-01-21 2006-08-24 ブリストル−マイヤーズ　スクイブ　カンパニー 新規アシルコエンザイムａ：モノアシルグリセロールアシルトランスフェラーゼ−３（ｍｇａｔ３）をコードするポリヌクレオチドおよびその用途
US7601694B2 (en) * 2003-02-20 2009-10-13 New York University CLK-peptide and SLK-peptide
US7662783B2 (en) * 2003-02-20 2010-02-16 New York University CLK-peptide and SLK-peptide
US7387998B2 (en) 2003-03-28 2008-06-17 New York University STQ peptides
EP1613273B1 (de) 2003-04-11 2012-06-13 MedImmune, LLC Rekombinante il-9-antikörper und ihre verwendung
MXPA06000508A (es) 2003-07-18 2006-04-05 Amgen Inc Agentes de union especifica al factor del crecimiento de los hepatocitos.
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP1660186B1 (de) 2003-08-18 2013-12-25 MedImmune, LLC Humanisierung von antikörpern
US7371381B2 (en) * 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
US20050271650A1 (en) * 2004-02-17 2005-12-08 Cellmatrix, Inc. Method and composition for angiogenesis inhibition
US7977463B2 (en) 2004-03-12 2011-07-12 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
CN102653515A (zh) 2004-06-15 2012-09-05 宝利麦迪克斯股份有限公司 聚阳离子化合物及其用途
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
US20070275874A1 (en) * 2004-09-03 2007-11-29 Yale University Use of Leptin in Wound Healing
EP1812468A2 (de) * 2004-09-15 2007-08-01 K.U.Leuven Research & Development Mit dem platelet factor 4 variant 1 (pf4var1) verwandte angiogeneseinhibitoren
US7700720B2 (en) 2004-09-21 2010-04-20 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20060204512A1 (en) 2004-09-23 2006-09-14 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
EP2422811A2 (de) 2004-10-27 2012-02-29 MedImmune, LLC Modulation von Antikörperspezifität mittels Anpassung der Affinität zu verwandten Antigenen
CA2588273A1 (en) * 2004-11-19 2006-05-26 Bioquanta Corp. Pf4 pharmacophores and their uses
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
US20060216237A1 (en) * 2005-03-11 2006-09-28 Brooks Peter C Inhibition of angiogenesis and tumor development by IGFBP-4
US20060216236A1 (en) * 2005-03-11 2006-09-28 Brooks Peter C Methods of inhibiting alphavBeta3-mediated angiogenesis and tumor development
US20060240002A1 (en) * 2005-03-11 2006-10-26 Brooks Peter C Methods of inhibiting angiogenesis-dependent conditions mediated by cryptic epitopes of extracellular matrix components
EP1869192B1 (de) 2005-03-18 2016-01-20 MedImmune, LLC Rahmenmischung von antikörpern
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
KR101446989B1 (ko) 2005-05-06 2014-10-15 지모제넥틱스, 인코포레이티드 Ｉｌ-31 단클론성 항체 및 사용법
AU2006261920A1 (en) 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
WO2007008604A2 (en) * 2005-07-08 2007-01-18 Bristol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
CA2619654A1 (en) * 2005-08-24 2007-03-01 Cell Matrix Combination therapies for inhibiting integrin-extracellular matrix interactions
WO2007027906A2 (en) * 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1945261A4 (de) 2005-11-07 2010-05-12 Scripps Research Inst Zusammensetzungen und verfahren zur steuerung der spezifität von gewebefaktor-signalisierungen
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
ES2586825T3 (es) 2006-01-12 2016-10-19 Alexion Pharmaceuticals, Inc. Anticuerpos para OX-2/CD200 y usos de los mismos
ES2353482T3 (es) 2006-02-10 2011-03-02 Amgen, Inc Formas hidrato de amg706.
CA2650730A1 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
US20090298093A1 (en) * 2006-04-27 2009-12-03 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways
PT2029173T (pt) 2006-06-26 2016-11-02 Macrogenics Inc Anticorpos específicos fc rib e seus métodos de uso
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
RU2009111884A (ru) 2006-09-01 2010-10-10 Займоджинетикс, Инк. (Us) Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
EP2407548A1 (de) 2006-10-16 2012-01-18 MedImmune, LLC Moleküle mit reduzierter Halbwertzeit, Zusammensetzungen und ihre Verwendung
US9526759B2 (en) 2007-02-01 2016-12-27 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
CA2676173A1 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
EP1972639A3 (de) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagenzien zur Erkennung von Proteinphosphorylierung in Karzinom-Signalwegen
EP1975184A3 (de) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serin- oder Threonin-Phosphorylationsorte
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
AU2008232903B9 (en) 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP1983003A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylationsstellen und spezifische Antikörper
EP1983002A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylations-Stellen und spezifische Antikörper
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
ES2540807T3 (es) 2007-05-04 2015-07-13 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Dominios variables de anticuerpos de conejo modificados por ingeniería genética y usos de los mismos
HUE026728T2 (en) 2007-05-14 2016-06-28 Medimmune Llc A method for reducing eosinophil levels
MX2010001918A (es) 2007-08-21 2010-03-11 Amgen Inc Proteinas enlazadas al antigeno humano de celula de cepa mcdonough de felino.
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2062920A3 (de) 2007-11-21 2009-06-17 Peter Hornbeck Proteinphosphorylation durch basophilische Serin-/Threonin-Kinasen in Insulinsignalisierungspfaden
LT2796466T (lt) 2007-12-07 2018-02-26 Zymogenetics, Inc. Humanizuotų antikūnų molekulės, specifinės il-31 atžvilgiu
BRPI0907046A2 (pt) 2008-01-18 2015-07-28 Medimmune Llc Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
US20120134984A1 (en) 2009-06-01 2012-05-31 Olga Lubman Molecules with extended half-lives and uses thereof
WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
LT2769737T (lt) 2009-07-20 2017-06-26 Bristol-Myers Squibb Company Anti-ctla4 antikūno derinys su etopozidu, skirtas sinerginiam proliferacinių ligų gydymui
EP2464657B1 (de) 2009-08-10 2015-04-01 MorphoSys AG Neue screening-verfahren zur identifizierung von antikörpern und deren fragmente, die ein antigen mit enzymatischer aktivität binden
ES2553440T3 (es) 2009-08-13 2015-12-09 Crucell Holland B.V. Anticuerpos contra el virus sincitial respiratorio humano (VSR) y método de uso
US8840889B2 (en) 2009-08-13 2014-09-23 The Johns Hopkins University Methods of modulating immune function
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
PH12012502193A1 (en) 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EA201291180A1 (ru) 2010-05-06 2013-05-30 Новартис Аг Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
TWI627964B (zh) 2010-07-09 2018-07-01 傑森疫苗防護公司 抗-人類呼吸道融合性病毒（ｒｓｖ）抗體及其使用方法
SG10201913700SA (en) 2010-07-09 2020-03-30 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
PL2606070T3 (pl) 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
CA2809369A1 (en) 2010-08-27 2012-03-01 Stem Centrx, Inc. Notum protein modulators and methods of use
BR112013005116A2 (pt) 2010-09-03 2019-09-24 Stem Centrx Inc moduladores e métodos de uso
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
MX356400B (es) 2010-12-08 2018-05-28 Abbvie Stemcentrx Llc Moduladores novedosos y metodos de uso.
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
PT2688887E (pt) 2011-03-23 2015-07-06 Amgen Inc Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
WO2013025939A2 (en) 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
US20150044208A1 (en) 2011-09-23 2015-02-12 Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, Sa Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
WO2013067054A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
AU2012332021B8 (en) 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
SG11201401717VA (en) 2011-11-04 2014-05-29 Novartis Ag Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
US9453073B2 (en) 2011-12-02 2016-09-27 Eli Lilly And Company Anti-glucagon antibodies and uses thereof
US20130273029A1 (en) 2011-12-05 2013-10-17 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
AU2012349735B2 (en) 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
PE20150159A1 (es) 2011-12-21 2015-02-08 Novartis Ag Composiciones y metodos para anticuerpos que actuan sobre el factor p
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
KR102099073B1 (ko) 2012-02-24 2020-04-10 애브비 스템센트알엑스 엘엘씨 항 ｓｅｚ6 항체들 및 사용 방법
EP3093294A1 (de) 2012-02-24 2016-11-16 Stemcentrx, Inc. Dll3-antikörper und verfahren zur verwendung
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2013149219A2 (en) 2012-03-30 2013-10-03 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
TWI702955B (zh) 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
RU2681730C2 (ru) 2012-07-25 2019-03-12 Селлдекс Терапьютикс Инк. Антитела против kit и их применения
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
HUE053669T2 (hu) 2012-12-05 2021-07-28 Novartis Ag Készítmények és eljárások EPO-t célzó antitestekre
MX2015007931A (es) 2012-12-18 2015-10-05 Novartis Ag Composiciones y metodos que utilizan una etiqueta de peptido que se une a hialuronano.
RU2019109456A (ru) 2013-02-22 2019-04-10 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые конъюгаты антител и их применения
CN105246916A (zh) 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
SMT201700530T1 (it) 2013-03-14 2018-01-11 Bristol Myers Squibb Co Combinazione di agonista di dr5 e antagonista anti-pd-1 e metodi d'uso
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
JP6824735B2 (ja) 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US9475874B2 (en) 2013-08-26 2016-10-25 MabVax Therapeutics, Inc. Nucleic acids encoding human antibodies to sialyl-lewisa
JP2016538318A (ja) 2013-08-28 2016-12-08 ステムセントリックス， インコーポレイテッド 新規ｓｅｚ６モジュレーターおよび使用方法
WO2015031698A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Site-specific antibody conjugation methods and compositions
WO2015065954A1 (en) 2013-11-04 2015-05-07 Pfizer, Inc. Anti-efna4 antibody-drug conjugates
AU2015209131B2 (en) 2014-01-24 2020-06-25 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
KR20170008202A (ko) 2014-02-21 2017-01-23 애브비 스템센트알엑스 엘엘씨 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
ES3042252T3 (en) 2014-03-17 2025-11-19 Adverum Biotechnologies Inc Compositions and methods for enhanced gene expression in cone cells
AU2015240599B2 (en) 2014-04-04 2020-11-19 Bionomics, Inc. Humanized antibodies that bind LGR5
WO2015175375A1 (en) 2014-05-13 2015-11-19 Short Jay M Conditionally active biological proteins
CN106413750B (zh) 2014-05-16 2022-04-29 免疫医疗有限责任公司 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
CA2950602C (en) 2014-06-04 2021-07-20 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside gd2
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
EP3160990A2 (de) 2014-06-25 2017-05-03 Novartis AG Zusammensetzungen und verfahren für proteine mit langer wirkung
EP3160991A2 (de) 2014-06-25 2017-05-03 Novartis AG Zusammensetzungen und verfahren für proteine mit langer wirkung
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
PT3177642T (pt) 2014-08-07 2022-02-14 Novartis Ag Anticorpos semelhantes a angiopoietina 4 e métodos de uso
KR20170044115A (ko) 2014-09-03 2017-04-24 바이오아트라, 엘엘씨 동일한 진핵생물 세포 생산 숙주 내 조건부 활성 생체 단백질의 발견 및 제조
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA2970352A1 (en) 2014-12-11 2016-06-16 Pierre Fabre Medicament Anti-c10orf54 antibodies and uses thereof
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
AU2016222830B2 (en) 2015-02-24 2021-02-25 Bioatla Llc Conditionally active biological proteins
CN114480502A (zh) 2015-03-02 2022-05-13 阿德夫拉姆生物技术股份有限公司 用于将多核苷酸玻璃体内递送到视网膜视锥的组合物和方法
HRP20230046T1 (hr) 2015-03-03 2023-03-03 Kymab Limited Protutijela, upotreba i postupci
CA2985125A1 (en) 2015-05-06 2016-11-10 Janssen Biotech, Inc. Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
CN107614526A (zh) 2015-06-05 2018-01-19 诺华股份有限公司 靶向骨形成蛋白9(bmp9)的抗体及其方法
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
RU2752530C2 (ru) 2015-08-03 2021-07-29 Новартис Аг Способы лечения расстройств, связанных с fgf21
AU2016320748B2 (en) 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
PT3347377T (pt) 2015-09-09 2021-04-30 Novartis Ag Anticorpos que se ligam à linfopoietina do estroma tímico (tslp) e métodos de utilização dos anticorpos
HK1251158A1 (zh) 2015-09-29 2019-01-25 细胞基因公司 Pd-1结合蛋白及其使用方法
MX2018005063A (es) 2015-11-02 2018-12-10 Bioatla Llc Polipéptidos condicionalmente activos.
EP3383891A1 (de) 2015-12-04 2018-10-10 Novartis AG Antikörpercytokingepfropfte zusammensetzungen und verfahren zur verwendung zur immunoregulierung
UY37030A (es) 2015-12-18 2017-07-31 Novartis Ag Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
EP3851457A1 (de) 2016-01-21 2021-07-21 Novartis AG Gegen cll-1 gerichtete multispezifische moleküle
EP3432925A4 (de) 2016-03-22 2019-11-06 Bionomics Limited Verabreichung eines monoklonalen anti-lgr5-antikörpers
CN109071647B (zh) 2016-04-27 2022-11-22 诺华股份有限公司 抗生长分化因子15的抗体及其用途
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
AU2017283787B2 (en) 2016-06-15 2020-09-17 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
EP3481866B1 (de) 2016-07-06 2024-07-24 Bristol-Myers Squibb Company Kombination von tim-4-antagonisten und pd-1-antagonisten und verfahren zur verwendung
WO2018053401A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
AU2017329024A1 (en) 2016-09-19 2019-03-21 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
EP3515495A4 (de) 2016-09-26 2020-08-26 Ensemble Group Holdings Verfahren zur beurteilung und behandlung von krebs bei menschen mit dysregulierten lymphatischen systemen
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
NZ754994A (en) 2016-12-22 2022-12-23 Amgen Inc Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
KR102702288B1 (ko) 2016-12-23 2024-09-05 노파르티스 아게 항-인자 XI/XIa 항체를 사용한 치료 방법
US11168147B2 (en) 2016-12-23 2021-11-09 Novartis Ag Factor XI antibodies and methods of use
WO2018146594A1 (en) 2017-02-08 2018-08-16 Novartis Ag Fgf21 mimetic antibodies and uses thereof
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
IL322309A (en) 2017-05-24 2025-09-01 Novartis Ag IL2 antibody grafted proteins and methods of use in cancer treatment
CN111107868A (zh) 2017-05-24 2020-05-05 诺华股份有限公司 抗体细胞因子移植蛋白及使用方法
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
ES2928576T3 (es) 2017-09-08 2022-11-21 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
EP3694889A1 (de) 2017-10-13 2020-08-19 Boehringer Ingelheim International GmbH Humane antikörper gegen thomsen-nouvelle (tn)-antigen
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
CA3099118A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
EP3790886B1 (de) 2018-05-10 2024-06-26 Amgen Inc. Kras g12c-inhibitoren zur behandlung von krebs
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
EP3802535B1 (de) 2018-06-01 2022-12-14 Amgen, Inc Kras-g12c-inhibitoren und verfahren zur verwendung davon
KR20250151605A (ko) 2018-06-01 2025-10-21 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
CA3099799A1 (en) 2018-06-11 2019-12-19 Amgen Inc. Kras g12c inhibitors for treating cancer
MA51848A (fr) 2018-06-12 2021-04-21 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA53160A (fr) 2018-07-20 2021-05-26 Pf Medicament Récepteur pour vista
PE20211491A1 (es) 2018-09-27 2021-08-11 Celgene Corp PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
US11053226B2 (en) 2018-11-19 2021-07-06 Amgen Inc. KRAS G12C inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MA54546A (fr) 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
AU2019401495B2 (en) 2018-12-20 2025-06-26 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
EA202191730A1 (ru) 2018-12-20 2021-08-24 Эмджен Инк. Ингибиторы kif18a
KR20210146287A (ko) 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. 이환식 헤테로아릴 화합물 및 이의 용도
CN113727758A (zh) 2019-03-01 2021-11-30 锐新医药公司 双环杂环基化合物及其用途
CN113874392B (zh) 2019-03-28 2025-10-21 丹尼斯科美国公司 工程化抗体
EP3738593A1 (de) 2019-05-14 2020-11-18 Amgen, Inc Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
EP3972973A1 (de) 2019-05-21 2022-03-30 Amgen Inc. Festkörperformen
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
TWI905099B (zh) 2019-05-21 2025-11-21 瑞士商諾華公司 Cd19 結合分子及其用途
WO2021026098A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
JP7640521B2 (ja) 2019-08-02 2025-03-05 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
CN114391012B (zh) 2019-08-02 2025-10-31 美国安进公司 作为kif18a抑制剂的吡啶衍生物
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
EP4048671B1 (de) 2019-10-24 2026-03-18 Amgen Inc. Pyridopyrimidinderivate als kras-g12c- und kras-g12d-inhibitoren zur behandlung von krebs
KR20220109407A (ko) 2019-11-04 2022-08-04 레볼루션 메디슨즈, 인크. Ras 억제제
JP7823816B2 (ja) 2019-11-04 2026-03-04 レヴォリューション・メディスンズ，インコーポレイテッド Ｒａｓ阻害剤
WO2021097207A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
JP2023501528A (ja) 2019-11-14 2023-01-18 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CN114929279A (zh) 2020-01-07 2022-08-19 锐新医药公司 Shp2抑制剂给药和治疗癌症的方法
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
EP4143224A1 (de) 2020-05-01 2023-03-08 Novartis AG Immunglobulinvarianten
WO2021220215A1 (en) 2020-05-01 2021-11-04 Novartis Ag Engineered immunoglobulins
TW202212354A (zh) 2020-08-03 2022-04-01 美商健生生物科技公司 用於病毒治療劑中之多向生物運輸的材料及方法
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
CR20230165A (es) 2020-09-15 2023-06-02 Revolution Medicines Inc Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag Cd19 binding molecules and uses thereof
EP4271482A2 (de) 2020-12-31 2023-11-08 Alamar Biosciences, Inc. Bindemoleküle mit hoher affinität und/oder spezifität sowie verfahren zur herstellung und verwendung davon
IL308193A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
JP2025500878A (ja) 2021-12-17 2025-01-15 ジェンザイム・コーポレーション Ｓｈｐ２阻害剤としてのピラゾロピラジン化合物
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
EP4227307A1 (de) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazinverbindungen als shp2-inhibitoren
IL314883A (en) 2022-03-07 2024-10-01 Amgen Inc A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
EP4514846A1 (de) 2022-04-26 2025-03-05 Novartis AG Gegen il-13 und il-18 gerichtete multispezifische antikörper
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN114805536B (zh) * 2022-06-24 2022-09-02 北京百臻生物技术有限公司 一种人血小板因子4蛋白突变体及其应用
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
EP4554619A1 (de) 2022-07-15 2025-05-21 Danisco US Inc. Verfahren zur herstellung monoklonaler antikörper
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
CN116375859A (zh) * 2023-06-05 2023-07-04 北京大学第一医院 一种抗vWF/PF4蛋白的单克隆抗体及其应用
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025104604A1 (en) 2023-11-14 2025-05-22 Janssen Pharmaceuticals, Inc. Anti-respiratory syncytial virus antibodies and uses thereof
TW202542151A (zh) 2023-12-22 2025-11-01 美商銳格醫藥有限公司 Ｓｏｓ１抑制劑及其用途
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4737580A (en) * 1985-03-15 1988-04-12 Oncogen Platelet related growth regulator
US4645828A (en) * 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
US4824986A (en) * 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate
SE8505716D0 (sv) * 1985-12-03 1985-12-03 Biocarb Ab Novel compounds and conjugates thereof
EP0267038A3 (de) * 1986-11-06 1989-07-12 The University Of British Columbia Effizientere Kopplung in wasserfreien Medien
JPH01503513A (ja) * 1987-03-02 1989-11-30 オンコゲン 血小板関連増殖調節剤
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases

Also Published As

Publication number Publication date
EP0723015A1 (de) 1996-07-24
DE69028739D1 (de) 1996-11-07
US5112946A (en) 1992-05-12
DE69028739T2 (de) 1997-02-13
DK0407122T3 (da) 1997-02-17
JPH0363297A (ja) 1991-03-19
CA2019086A1 (en) 1991-01-06
ES2092493T3 (es) 1996-12-01
EP0407122A1 (de) 1991-01-09
GR3021658T3 (en) 1997-02-28
EP0407122B1 (de) 1996-10-02

Similar Documents

Publication Publication Date Title
ATE143698T1 (de) Modifizierte pf4-zusammensetzung und methoden zu deren verwendung
ES2013226A4 (es) Metodo y composiciones proveiendo quimicoluminiscencia mejorada de 1,2-dioxanos
ES2052871T3 (es) Preparacion de bis (3,5-di-t-butil-4-hidroxifeniltio)metano.
FI925098A7 (fi) Ihmisen papilloomavirusten 1,5,6,8,11,16,18,31,33 ja 56 synteettisiä p eptidejä, jotka ovat käyttökelpoisia immunoanalyysissä diagnostisiin t arkoituksiin
NO881406D0 (no) Injiserbare materialer for forstoerresle av mykt vev.
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
FR2597883B1 (fr) Nouveaux polypeptides activateurs du plasminogene de type tissulaire humain
ATE87006T1 (de) Peptidderivate, verfahren zu ihrer herstellung und ihre verwendung.
ATE204570T1 (de) Piperazinderivate
AU4626389A (en) Use of minoxidil for wound healing
ATE96997T1 (de) Kosmetische zusammensetzung.
DK0478631T3 (da) Målsøgende midler
ATE41773T1 (de) 4,5-dihydro-4-oxo-2((2-transphenylcyclopropyl)amino>-3-furancarbonsaeuren und derivate davon.
DE69832197D1 (de) Rantes mutanten und deren therapeutische verwendungen
ES2011131A6 (es) Vastago de un aparato quirutgico de sutura.
CA2011371A1 (en) Rapid hair ph indication and solution therefor
IT1223336B (it) Composizione bituminosa e suo impiego nel settore dell'impermeabilizzazione
DE69029089D1 (de) Schneller Nachweis des Haar-pH-Wertes und dazugehörige Lösung
FR2643900B1 (fr) Fonctionnalisation en position n + 1 de derives aryliques disubstitues en position n et n + 2
PT84602A (de) Verwendung von substituierten n-trichlormethylthiohydantionen in kombination mit bis-(2,4-diamino-s-triazin-6-yl)-oligosulfiden in vulkanisierbaren kautschukmischungen und derartige kautschukmischungen
IT1216124B (it) Metodo per l'analisi in tempo reale dei movimenti mandibolari umani.
DE3862260D1 (de) Teil zum verbinden von zwei sich kreuzenden profilierten elementen mit eingebauter dichtung.
FR2648813B1 (fr) Nouveaux derives terpeniques, leur preparation et leur emploi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee